Tislelizumab plus sitravatinib as adjuvant therapy for patients with hepatocellular carcinoma at high risk of recurrence after surgical resection: Preliminary analysis of a multi-center, non-randomized, open-label phase 2 study

被引：0
|
作者：
Wang, Jiabei
Peng, Tao
Liu, Chang
Zhang, Ling
Zhu, Guangzhi
Zhang, Xiaogang
Wang, Xiaoqian
Liu, Lianxin
机构：
[1] USTC, Affiliated Hosp 1, Hefei, Peoples R China
[2] Guangxi Med Univ, Affiliated Hosp 1, Nanning, Peoples R China
[3] Xi An Jiao Tong Univ, Affiliated Hosp 1, Xian, Peoples R China
[4] Zhengzhou Univ, Affiliated Canc Hosp, Zhengzhou, Peoples R China
[5] Univ Sci & Technol China, Div Life Sci & Med, Affiliated Hosp 1, Hefei, Peoples R China
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2024年 / 42卷 / 16期
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
e16239
引用
收藏
页数：1
相关论文
共 50 条
  • [21] An open-label, non-randomized, multi-center phase I study evaluating the safety, tolerability, pharmacokinetics and preliminary efficacy of bi-ligand-drug conjugate CBP-1018 in patients with advanced solid tumors
    Li, Kaiwen
    Shi, Yehui
    Wu, Junyan
    Zhou, Liyan
    Ye, Suiwen
    Lai, Xiuping
    Huang, Robert
    Teng, Yan
    Yu, Jiangang
    Chai, Xiaoyan
    Huang, Hai
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [22] A prospective non-randomized open label multi-center study to evaluate the effect of an iliofemoral arteriovenous fistula on blood pressure in patients with therapy-resistant hypertension
    Brouwers, S.
    Droogmans, S.
    Dolan, E.
    Galvin, J.
    Dupont, A.
    Van Camp, G.
    Schoors, D.
    EUROPEAN HEART JOURNAL, 2013, 34 : 654 - 655
  • [23] Tislelizumab plus tyrosine kinase inhibitor versus active surveillance in patients with ablated high-risk hepatocellular carcinoma: An open-label, parallel controlled, prospective cohort study
    Pan, Shida
    Wang, Siyu
    Tian, Jiahe
    Shen, Yingjuan
    Yang, Luo
    Liu, Xiaomeng
    Yu, Yingying
    Wang, Yilin
    Qiu, Qin
    Luan, Junqing
    Fan, Xing
    Meng, Fanping
    JOURNAL OF CLINICAL ONCOLOGY, 2024, 42 (16)
  • [24] A randomized, controlled, multi-center, open-label study of adjuvant nab-paclitaxel plus S-1 (AS) versus capecitabine plus oxaliplatin (CapeOX) for stage III gastric cancer after D2 resection.
    Yu, Pengfei
    Du, Yian
    Xu, Zhiyuan
    Yang, Litao
    Ying, Jieer
    Wang, Yongxiang
    Chen, Ping
    Wei, Yunhai
    Xu, Hongtao
    Xu, Nong
    Cheng, Xiangdong
    JOURNAL OF CLINICAL ONCOLOGY, 2022, 40 (16)
  • [25] Cell-free stem cell-derived extract formulation for treatment of knee osteoarthritis: study protocol for a preliminary non-randomized, open-label, multi-center feasibility and safety study
    Gupta, Ashim
    Maffulli, Nicola
    Rodriguez, Hugo C.
    Mistovich, R. Justin
    Delfino, Kristin
    Cady, Craig
    Fauser, Anne-Marie
    Cundiff, Echo D.
    Martinez, Marte A.
    Potty, Anish G.
    JOURNAL OF ORTHOPAEDIC SURGERY AND RESEARCH, 2021, 16 (01)
  • [26] Cell-free stem cell-derived extract formulation for treatment of knee osteoarthritis: study protocol for a preliminary non-randomized, open-label, multi-center feasibility and safety study
    Ashim Gupta
    Nicola Maffulli
    Hugo C. Rodriguez
    R. Justin Mistovich
    Kristin Delfino
    Craig Cady
    Anne-Marie Fauser
    Echo D. Cundiff
    Marte A. Martinez
    Anish G. Potty
    Journal of Orthopaedic Surgery and Research, 16
  • [27] A randomized, open-label, parallel, multi-center Phase IV study to compare the efficacy and safety of atorvastatin 10 and 20 mg in high-risk Asian patients with hypercholesterolemia
    Kim, Ji Bak
    Song, Woo Hyuk
    Park, Jong Sung
    Youn, Tae-Jin
    Park, Yong Hyun
    Kim, Shin-Jae
    Ahn, Sung Gyun
    Doh, Joon-Hyung
    Cho, Yun-Hyeong
    Kim, Jin Won
    PLOS ONE, 2021, 16 (01):
  • [28] Open-label, multi-center, non-randomized, single-arm study to evaluate the safety and efficacy of dendritic cell immunotherapy in patients with refractory solid malignancies, on supportive care
    Bapsy, Poonamalle Parthasarathy
    Sharan, Bandana
    Kumar, Chaitanya
    Das, Rajeev Patrick
    Rangarajan, Bharath
    Jain, Minish
    Attili, Venkata Sathya Suresh
    Subramanian, Sundaram
    Aggarwal, Shyam
    Srivastava, Mala
    Vaid, Ashok
    CYTOTHERAPY, 2014, 16 (02) : 234 - 244
  • [29] Open-label randomized multi-center phase 2 study: gemcitabine cisplatin plus avelumab or gemcitabine cisplatin as first-line treatment of patients with locally advanced or metastatic urothelial bladder carcinoma: GCisAve
    Gross-Goupil, Marine
    Domblides, Charlotte
    Lefort, Felix
    Ravaud, Alain
    BULLETIN DU CANCER, 2020, 107 (05) : ES1 - ES7
  • [30] Imbrave050: Phase 3 Study of Adjuvant Atezolizumab plus Bevacizumab vs Active Surveillance in Patients with Hepatocellular Carcinoma at High Risk of Disease Recurrence after Resection or Ablation
    Yopp, Adam Charles
    Cheng, Ann-Lii
    Kaseb, Ahmed Omar
    JOURNAL OF THE AMERICAN COLLEGE OF SURGEONS, 2023, 237 (05) : S19 - S19
12345